CIBC Asset Management Inc Grows Holdings in Zimmer Biomet Holdings, Inc. $ZBH

CIBC Asset Management Inc lifted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 67.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 46,516 shares of the medical equipment provider’s stock after acquiring an additional 18,769 shares during the quarter. CIBC Asset Management Inc’s holdings in Zimmer Biomet were worth $4,183,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Goldman Sachs Group Inc. grew its position in shares of Zimmer Biomet by 24.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,018,387 shares of the medical equipment provider’s stock worth $91,573,000 after buying an additional 199,446 shares during the period. Westpac Banking Corp grew its position in shares of Zimmer Biomet by 26.3% in the 4th quarter. Westpac Banking Corp now owns 2,424 shares of the medical equipment provider’s stock worth $218,000 after buying an additional 504 shares during the period. Natixis Advisors LLC grew its position in shares of Zimmer Biomet by 16.8% in the 4th quarter. Natixis Advisors LLC now owns 112,845 shares of the medical equipment provider’s stock worth $10,147,000 after buying an additional 16,210 shares during the period. AXQ Capital LP purchased a new stake in shares of Zimmer Biomet in the 4th quarter worth about $230,000. Finally, Minneapolis Portfolio Management Group LLC grew its position in shares of Zimmer Biomet by 3.3% in the 4th quarter. Minneapolis Portfolio Management Group LLC now owns 272,894 shares of the medical equipment provider’s stock worth $24,539,000 after buying an additional 8,780 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $87.50 on Friday. The stock has a market cap of $16.93 billion, a price-to-earnings ratio of 22.73, a PEG ratio of 2.02 and a beta of 0.47. The firm’s 50-day moving average is $87.68 and its 200 day moving average is $90.48. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The company had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. Zimmer Biomet’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.49 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be paid a $0.24 dividend. The ex-dividend date is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s payout ratio is presently 24.94%.

Analyst Ratings Changes

A number of analysts have recently weighed in on ZBH shares. Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, April 7th. Canaccord Genuity Group set a $83.00 target price on shares of Zimmer Biomet in a research report on Wednesday, April 29th. BTIG Research reiterated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. William Blair initiated coverage on shares of Zimmer Biomet in a research note on Friday, February 20th. They issued a “market perform” rating on the stock. Finally, Stifel Nicolaus dropped their price target on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $102.70.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. This represents a 20.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider owned 27,251 shares in the company, valued at $2,252,022.64. This represents a 15.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 1.28% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.